California Debates Whether to Become Stem Cell Heavyweight
By Gretchen Vogel,
Science
| 09. 10. 2004
[Quotes CGS's Richard Hayes]
California Debates Whether to Become Stem Cell Heavyweight
Gretchen Vogel
Science
September 10, 2004
President George W. Bush may end up doing California stem cell researchers a huge favor. Spurred by the Bush Administration's restrictions on funding for human embryonic stem (ES) cells, patient advocates, venture capitalists, and research leaders have launched a campaign to persuade California voters to pass an unprecedented ballot proposal, called Proposition 71, that would allocate $3 billion for the field over the next 10 years.
If the measure passes in November--and early polls say it's still too close to call (Science, 27 August, p. 1225)--California would spend nearly $300 million a year on human ES cell research, almost 50% more than the $214 million the National Institutes of Health (NIH) spent on all human stem cell research--both embryonic and nonembryonic--in 2003. "It will change the landscape of where this work is done," says Douglas Melton of Harvard University, who because of the White House's restrictions has had to set up a privately funded lab to derive new human ES cell lines. "California will become a...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...